Search

Your search keyword '"Yamashita, Makiko"' showing total 406 results

Search Constraints

Start Over You searched for: Author "Yamashita, Makiko" Remove constraint Author: "Yamashita, Makiko"
406 results on '"Yamashita, Makiko"'

Search Results

6. Immune microenvironment, homologous recombination deficiency, and therapeutic response to neoadjuvant chemotherapy in triple-negative breast cancer: Japan Breast Cancer Research Group (JBCRG)22 TR

8. Molecular subtypes of lung adenocarcinoma present distinct immune tumor microenvironments

10. Interleukin‐4 induced 1‐mediated resistance to an immune checkpoint inhibitor through suppression of CD8+ T cell infiltration in melanoma.

11. Investigating the immunological function of alpha-2-glycoprotein 1, zinc-binding in regulating tumor response in the breast cancer microenvironment

12. FIGURE 5 from Tumor-infiltrating Leukocyte Profiling Defines Three Immune Subtypes of NSCLC with Distinct Signaling Pathways and Genetic Alterations

13. Table S3 from Tumor-infiltrating Leukocyte Profiling Defines Three Immune Subtypes of NSCLC with Distinct Signaling Pathways and Genetic Alterations

14. FIGURE 3 from Tumor-infiltrating Leukocyte Profiling Defines Three Immune Subtypes of NSCLC with Distinct Signaling Pathways and Genetic Alterations

15. Tumor-infiltrating leukocyte profiling defines three immune subtypes of NSCLC with distinct signaling pathways and genetic alterations

17. Supplementary Figures 1-7, Supplementary Tables 1-8, 12 from Transient Depletion of CD4+ Cells Induces Remodeling of the TCR Repertoire in Gastrointestinal Cancer

18. Table S11 from Transient Depletion of CD4+ Cells Induces Remodeling of the TCR Repertoire in Gastrointestinal Cancer

19. Data from Transient Depletion of CD4+ Cells Induces Remodeling of the TCR Repertoire in Gastrointestinal Cancer

20. Abstract P5-02-42: Soluble CD163 may be a predictive biomarker of the efficacy of nivolumab plus chemotherapy in patients with HER2-negative metastatic breast cancer (WJOG9917BTR)

21. Abstract P2-20-16: Hormone receptor expression is associated with specific immunological profiles in the breast cancer microenvironment

22. First-in-human phase 1 study of IT1208, a defucosylated humanized anti-CD4 depleting antibody, in patients with advanced solid tumors

23. Comprehensive biomarker analysis from phase II study of nivolumab in patients with thymic carcinoma

24. Additional file 1 of Expression of hormone receptors is associated with specific immunological profiles of the breast cancer microenvironment

32. Efficient Acquisition of Antigen-Specific Human Monoclonal Antibody by Using Peripheral Blood Mononuclear Cells Immunized In Vitro : Efficient Cloning of Human Monoclonal Antibody Gene

34. Expression of hormone receptors is associated with specific immunological profiles of the breast cancer microenvironment

35. Telomere Shortening in Cancer Cells by Electrolyzed-Reduced Water

37. Abstract P4-04-09: Systematic analysis of immune cell composition revealed immunological profile of breast cancer microenvironment represented by histologically assessed tumor-infiltrating lymphocyte and PD-L1 expression

39. Additional file 1 of Immune microenvironment, homologous recombination deficiency, and therapeutic response to neoadjuvant chemotherapy in triple-negative breast cancer: Japan Breast Cancer Research Group (JBCRG)22 TR

40. Immunological Profiles of The Breast Cancer Microenvironment Represented by Tumor-Infiltrating Lymphocytes and PD-L1 Expression

41. Pretreatment tumour immune microenvironment predicts clinical response and prognosis of muscle-invasive bladder cancer in the neoadjuvant chemotherapy setting

44. Immune cell composition and immunological profiles of the breast cancer microenvironment represented by histologically assessed tumor-infiltrating lymphocytes and PD-L1 expression: A systematic analysis

48. Transient Depletion of CD4+ Cells Induces Remodeling of the TCR Repertoire in Gastrointestinal Cancer

49. Abstract PS4-14: Immunological analysis of the combination therapy of nivolumab, paclitaxel and bevacizumab in patients with HER2-negative MBC in NEWBEAT trial (WJOG9917BTR)

50. Depletion of cellular cholesterol enhances macrophage MAPK activation by chitin microparticles but not by heat-killed Mycobacterium bovis BCG

Catalog

Books, media, physical & digital resources